BACKGROUND: The Richmond Agitation-Sedation Scale (RASS) is commonly used to assess psychomotor activity; however, to the authors' knowledge, its minimal clinically important difference (MCID) has not been determined to date. The objective of the current study was to identify the MCID for RASS using 2 anchor-based approaches. METHODS: The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium. The primary outcome was change in RASS (10-point numeric rating scale ranging from -5 [unarousable] to 14 [combative]) from baseline to 8 hours after treatment administration. The sensitivity-specificity and within-patient change methods were used to identify the MCID, with the anchor being patient comfort after the study intervention as perceived by caregivers and nurses. RESULTS: A total of 90 patients were randomized and 58 (64%) received the study medication for restlessness/ agitation (mean baseline RASS, 1.6). A total of 23 caregivers (61%) and 23 nurses (55%) perceived that the patient was more comfortable after treatment. Using the sensitivity-specificity method, the optimal RASS reduction was 4 points according to both caregivers (sensitivity of 61% and specificity of 80%; area under the curve, 0.71) and nurses (sensitivity of 73% and specificity of 84%; area under the curve, 0.78). The RASS cutoff value based on the within-patient change method was similar (-4.2 for caregivers and -4.0 for nurses). CONCLUSIONS: For patients with persistent restlessness/agitation, a reduction of 4 points in RASS was considered to be the MCID for both nurses and caregivers. These preliminary findings may have implications for sample size calculation and the interpretation of treatment effect in future delirium trials. Cancer 2018;124:2246-52.
INTRODUCTION
Delirium is a highly distressing and difficult-to-manage neuropsychiatric syndrome that commonly occurs within the last weeks to days of life. 1, 2 Greater than one-half of patients with delirium have hyperactive features characterized by restlessness and agitation, which can result in significant psychological distress among patients, their caregivers, and health care professionals, and may pose a safety concern for patients. 3 The management of agitated delirium is complicated by the paucity of randomized controlled trials with which to inform clinical practice, leading to few evidence-based treatment options for this devastating syndrome. There are many contributors to the lack of research concerning delirium, such as difficulties in enrolling extremely ill patients, scarce research funding, a shortage of academic investigators, and a limited number of validated assessment tools with which to examine delirium-related outcomes. 1 The Richmond Agitation-Sedation Scale (RASS) is one of the most commonly used instruments to assess the level of psychomotor agitation and sedation in clinical practice and research. This clinician-based observation scale is simple to use, easy to interpret, and has been validated in multiple care settings. 4 It has been incorporated as the primary or secondary outcome measure in several clinical trials regarding delirium. [5] [6] [7] [8] However, to the best of our knowledge, the minimal clinically important difference (MCID; ie, the smallest change in this scale that is clinically meaningful) for patients being treated for agitation has yet to be defined. Availability of the MCID for RASS would facilitate proper sample size justification for studies regarding agitated delirium, and also enable clinicians to properly interpret the study findings. In the current study, we conducted a post hoc secondary analysis of a recently completed randomized trial on agitated delirium to determine the MCID for RASS using the sensitivity-specific approach.
MATERIALS AND METHODS

Study Design
The current study was a secondary analysis of a doubleblind, randomized controlled trial to compare the use of single-dose lorazepam versus placebo as adjunctive therapy to haloperidol in patients with persistent agitated delirium. Details regarding the study methodology have been published recently. 6 Briefly, inclusion criteria included patients who were adults (aged 18 years); had a diagnosis of advanced cancer; were admitted to the acute palliative care unit at The University of Texas MD Anderson Cancer Center in Houston; had a diagnosis of delirium based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria; and had a RASS score of 12 within 24 hours of enrollment despite a scheduled haloperidol dose of 1 to 8 mg/day. Exclusion criteria included dementia, use of benzodiazepines or chlorpromazine within the past 48 hours, contraindications to neuroleptics (ie, Parkinson disease, myasthenia gravis, acute narrow angle glaucoma, seizure disorders, documented QTc prolongation, or hypersensitivity), or contraindications to benzodiazepines (ie, hypersensitivity).
At the time of enrollment to the current study, all patients were administered scheduled haloperidol at a dose of 2 mg intravenously every 6 hours and 2 mg intravenously every hour as needed for agitation. Once patients became restless/agitated (ie, RASS score 11) and required the rescue medication in the opinion of the bedside nurse, they were given either lorazepam at a dose of 3 mg in 25 mL of 0.9% normal saline plus haloperidol at a dose of 2 mg intravenously or an identically appearing placebo plus haloperidol at a dose of 2 mg intravenously. 6 At the beginning of the study, the RASS threshold for the administration of study medication was set at 12. This threshold was revised to a RASS score 11 after 7 months to ensure that patients who were restless also could receive study medications.
Data Collection
The primary outcome of the current study was change in the RASS score from baseline to 8 hours after administration of the study medication. RASS is a single item assessed by the bedside nurse. It is a 10-point ordinal scale that ranges from 14 to -5, in which 4 indicates combative, 3 indicates very agitated, 2 indicates agitated, 1 indicates restless, 0 indicates alert and calm, -1 indicates drowsy, -2 indicates light sedation, -3 indicates moderate sedation, -4 indicates deep sedation, and -5 indicates unarousable. RASS has been tested extensively for construct validity and has high interrater reliability (0.91). 4, [9] [10] [11] [12] We also asked the caregivers (legally authorized surrogate decision makers) and nurses to independently report their perceived level of patient comfort. 6 This was considered to be the anchor for MCID determination in the current study because one of the key goals of pharmacologic therapy in the setting of agitated delirium is to improve patient comfort. Both caregivers and nurses were blinded to study assignment and answered the following question on the day after treatment: "In my opinion, the patient was more comfortable after the study medication." The response was recorded on a 5-point Likert scale ranging from "strongly agree" to "agree," "neutral," "disagree," and "strongly disagree." For the purposes of analysis, "strongly agree" and "agree" were considered as agreement. In the current study, caregiver assessment was used as the main anchor, and the assessment of nurses as the secondary anchor.
Statistical Analysis
The study sample size was based on our calculation that 26 patients per treatment arm would allow us to detect a mean between-arm difference in the RASS score of 0.32 (effect size of 0.5, based on a standard deviation [SD] of 0.63) with an a of 5% using a 2-sided Student t test. 6 We summarized our data with descriptive statistics.
To determine the MCID for RASS, we adopted the statistical analysis plan previously used to identify the MCID for the Edmonton Symptom Assessment System. 13, 14 In the sensitivity-specificity approach, the caregiver's perceived level of patient comfort was used as the benchmark against which RASS changes were anchored and calibrated. Specifically, improvement was indicated by the caregiver answering "agree" or "strongly agree," whereas other answers (ie, "neutral," "disagree," and "strongly disagree") were considered as no improvement. We plotted the receiver operating characteristic curves with the true-positive rate (sensitivity) on the y-axis and the false-positive rate (1 indicates specificity) on the xaxis. We then calculated the area under the curve, and determined the optimal cutoff value for improvement based on the Youden J index and top left approaches. We repeated the same analysis using the perceived level of patient comfort by the nurse as the anchor.
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We also estimated the MCID using within-patient change by computing the average RASS change for the "agree" categories of the question regarding the perceived level of patient comfort because this category represented the smallest perceived change. 15 MCID often is estimated using the distributionbased approach, in which a SD of 0.5 in the baseline score is considered as a cutoff value. 16 However, the nature of the current study design resulted in a highly homogenous RASS score distribution at baseline because patients only initiated the study intervention when they reached the prespecified RASS threshold. Thus, the distribution approach was not used herein to estimate the MCID.
SAS statistical software (version 9.3; SAS Institute Inc, Cary, North Carolina) was used for statistical analysis. Statistical significance was declared when the P value was <.05.
RESULTS
Patient Characteristics
The demographics of the current study have been reported previously. 6 Among the 58 patients who received the study medication, 52 (90%) completed the first 8 hours of observation. The mean age of the patients was 65 years (range, 30-90 years); 27 patients (47%) were female, 44 (76%) were white, 46 (79%) had metastatic disease, and 53 (91%) had a Karnofsky performance status of 30% (Table 1 ). The most common malignancies were respiratory (14 patients; 24%) and gastrointestinal (13 patients; 22%). The median Memorial Delirium Assessment Scale was 29.5 (interquartile range, 20-30). A total of 28 patients (48%), 26 patients (45%), and 4 patients (7%), respectively, had RASS scores of 11, 12, and 13 at the time of administration of the study medication, with a mean RASS score of 1.6 (SD, 0.6). Table 2 shows the characteristics of the 58 caregivers included in the current study.
Change in RASS
As reported previously, 6 patients in the lorazepam/haloperidol treatment arm had a significant within-arm decrease in the RASS score within the first 30 minutes of administration of the study medication (mean change, -3.6; 95% confidence interval [95% CI], -4.3 to -2.9) and this effect was sustained at 8 hours (mean change, -4.1; 95% CI, -4.8 to -3.4). Patients in the placebo/haloperidol treatment arm also demonstrated a reduction in the RASS score at 30 minutes (mean change, -1.6; 95% CI, -2.2 to -1.0) and at 8 hours (mean change, -2.3; 95% CI, -2.9 to -1.6). By 8 hours, 17 of 26 patients (65%) in the lorazepam/haloperidol arm had a reduction of 4 points in RASS compared with 7 of 26 patients in the placebo/ haloperidol arm (27%) (P 5 .01, Fisher exact test).
Perceived Level of Patient Comfort
Data regarding the perceived level of patient comfort were available from 38 of 52 caregivers (73%; 19 in the lorazepam/haloperidol treatment arm and 19 in the placebo/ haloperidol treatment arm) and 42 nurses (81%; 22 in the lorazepam/haloperidol treatment arm and 20 in the placebo/haloperidol treatment arm). Missing data were due to death, patients being discharged before we were able to administer questions, or research staff that was unavailable (eg, on a weekend). As reported in the primary study, 6 16 patients in the lorazepam/haloperidol treatment arm (84%) and 7 patients in the placebo/haloperidol treatment arm (37%) were perceived by caregivers to be more comfortable after the study intervention; moreover, 17 patients in the lorazepam/haloperidol treatment arm (77%) and 6 patients in the placebo/haloperidol treatment arm (30%) were perceived by nurses to be more comfortable. For 12 patients, both the caregivers and nurses agreed that the patient was more comfortable. In 14 patients, both the caregivers and nurses perceived that the patient was not more comfortable after administration of the study medication. For 7 patients, the caregivers believed that the patient was more comfortable whereas the nurses disagreed, and for 3 patients the nurses reported that the patient was more comfortable whereas the caregivers disagreed. The interrater agreement was moderate (kappa, 0.45; 95% CI, 0.17-0.73 [P 5 .008]).
Minimal Clinically Important Difference
Using the sensitivity-specificity approach, the optimal cutoff value for RASS improvement was a 4-point reduction for both caregivers (sensitivity of 61% and specificity of 80%) and nurses (sensitivity of 73% and specificity of 84%) ( Table  3 ). Based on this cutoff value, the sensitivity was 61%, the specificity was 80%, the positive predictive value was 82%, and the negative predictive value was 57% for caregiver assessment, whereas the sensitivity was 73%, the specificity was 84%, the positive predictive value was 84%, and the negative predictive value was 73% for nursing assessment. The area under the receiver operating characteristic curve Abbreviations: 95% CI, 95% confidence interval; AUC, area under the receiver operating characteristic curve; RASS, Richmond Agitation-Sedation Scale. a The cutoff value was selected based on the largest Youden J value, which represents the point on the receiver operating characteristic (ROC) curve that represents the largest vertical distance from the ROC curve to the diagonal line of equality. The optimal cutoff value is highlighted in bold type. b The cutoff value was chosen based on the smallest top left value, which is the point on the ROC curve that represents the shortest distance to the top left corner of the graph (in which the sensitivity is 100% and the specificity is 100%). The optimal cutoff value is highlighted in bold type. c The AUC is an indicator of the ability of the scale to discriminate change. The AUCs for the ROC curves were >0.70, which suggest moderate to high discrimination. The P values for the AUCs were .03 for caregivers and .002 for nurses. .002]) for nurses, suggesting moderate to high discrimination (Fig. 1) . The RASS cutoff value based on the within-patient change method also was found to be highly consistent with the above analysis at -4.2 (SD, 0.6) for caregivers and -4.0 (SD, 1.8) for nurses.
DISCUSSION
In the current study, we found that the MCID for RASS improvement was a 4-point reduction using both the sensitivity-specificity approach and the within-patient change approach. Remarkably, this cutoff value was the same for both caregivers and nurses. We believe the preliminary findings of the current study have potential implications for clinical trial designs and interpretation.
The MCID often is determined using an anchorbased approach, and the choice of anchor is critical to define clinical significance. To the best of our knowledge, there is no universally accepted anchor with which to define clinical significance in the setting of agitated delirium. We elected to use perceived level of patient comfort as the anchor herein because one of the most important goals of palliative care is to maximize comfort through the alleviation of suffering. Patient comfort also is a key determinant of personalized symptom goals. 17 Although patient comfort may be affected by many factors other than agitation, such as pain and dyspnea control, the significant association noted between the perceived level of patient comfort and RASS change in the current study supports that the level of agitation/restlessness remains a main driver of comfort. The moderate to high level of discrimination in the RASS score further confirms this assessment's responsiveness to change.
To our knowledge, the current study is the first to examine the MCID for RASS in the setting of agitated delirium. We were surprised to find that the MCID for RASS was 4 points over the 10-point Likert scale, suggesting that a large magnitude of reduction in RASS was necessary for it to be considered as clinically meaningful. We believe the findings of the current study are robust because all 4 methods (2 assessors and 2 anchor-based approaches) arrived at the same cutoff value. One reason for this large MCID value may be related to the fact that we used the perceived level of patient comfort as an anchor. A significant shift in RASS may be necessary for patients to be considered as comfortable by surrogate observers, who likely have been troubled by the aggressive behavior and/or sleepless nights. In this specific setting of persistent agitation, a consistent level of moderate sedation may be preferred over light sedation.
This large MCID value has implications for the design of future clinical trials regarding delirium. First, the sample size required may be smaller than that for other symptoms. Given that delirium trials are complex by nature and difficult to conduct, this new insight supports that even small studies (<100 patients) may be adequately powered for hypothesis testing. Second, the intervention needs to have a relatively significant impact on agitation. For pharmacologic therapies, this means that the dose would need to be high enough or that medication combinations may be required to achieve the desired effect. 18, 19 Third, it is important to point out that a smaller magnitude does not necessarily indicate that the intervention is not clinically significant. Smaller changes in RASS may be associated with other clinical outcomes (eg, less use of rescue neuroleptics, the absence of any RASS score 11 during the 8-hour period) and need to be investigated further.
In addition to study design, findings from the current study may help us to better interpret the outcomes of clinical trials. For a patient with agitation at a RASS score of 11 or 12 at baseline, a reduction to a RASS score of -3 (moderately sedated) and -2 (mildly sedated), respectively, would be necessary for the patient to be considered as comfortable. This finding suggests that a RASS score of -1 or 0 may not be the optimal level of sedation, perhaps because patients on this trial had persistent delirium with agitation, which could be extremely distressing for caregivers and nurses alike. Applying this 4-point cutoff value, approximately 65% of patients in the lorazepam/haloperidol treatment arm and 27% of patients in the placebo/haloperidol treatment arm were able to achieve a clinical response by 8 hours.
A better understanding of the MCID also may have clinical implications for defining a clinical response. The results of the current study suggest that caregivers desire a significant shift in consciousness for patients with persistent agitation. The use of pharmacologic therapy for delirium in the palliative care setting is an area of intense debate. Although current clinical practice guidelines recommend neuroleptics such as haloperidol and olanzapine as first-line pharmacologic treatments for patients experiencing agitation in delirium, 20,21 some have cautioned against their use because a recent 3-arm randomized trial found that placebo was superior to risperidone and haloperidol. 5 However, several methodologic issues complicate its interpretation, including the composite primary outcome, which to our knowledge has not been validated, and the enrollment of patients with relatively low delirium symptom severity. 22 In contrast, the current randomized clinical trial in the setting of terminal delirium found that the administration of haloperidol alone resulted in a significant reduction in the RASS score (a validated primary outcome) and that the addition of lorazepam was significantly more effective. 6 More research is needed to identify the right medication(s) for the right indication in the right population. Patients with hyperactive delirium often receive higher doses of neuroleptics compared with those with hypoactive delirium; however, to the best of our knowledge, the optimal dosing has not been defined, resulting in wide variations in how neuroleptics are prescribed in practice. 19 One unique aspect of the current study was that we assessed patient comfort from the perspective of caregivers and nurses. Given that patients were delirious and unable to communicate, we needed to rely on these observers, who often spend a large amount of time by the bedside, to provide a surrogate response. It is interesting to note that there was only moderate concordance between the caregivers' assessment and that of the bedside nurses. This is consistent with previous studies regarding patientreported outcomes suggesting that the impressions of caregivers and nurses correlated with patient self-report, although the 2 groups had different perspectives. 23 It was reassuring that the same cutoff value for RASS reduction was considered clinically meaningful by both groups.
The current study has several limitations. First, the MCID was derived from a single randomized trial conducted in an acute palliative care unit. Patients in the current study were being treated for terminal restlessness/ agitation and therefore these findings may not be generalizable to other settings. Second, it is important to point out that a majority of study participants had a RASS score of 11 or 12 at the time of administration of the study medication. Further research is needed to determine whether the 4-point MCID cutoff value is applicable to patients with higher RASS scores. Third, the sample size was small and not specifically powered for this post hoc analysis. This limitation was compounded further by the fact that the anchor was missing in some patients. Thus, the MCID cutoff value should be considered as preliminary. Fourth, the primary outcome was change in RASS reduction from baseline to 8 hours whereas the anchor was collected between 8 and 24 hours after the study intervention. The level of sedation/agitation and other symptoms that occurred during this time interval may have contributed to the perceived level of patient comfort. Fifth, we only assessed the perceived level of patient comfort using a single question. Qualitative studies may help to better understand how caregivers and nurses define patient comfort within the context of refractory terminal delirium and to identify a personalized sedation goal.
Using 4 different anchor-based methods, the results of the current study demonstrated that a reduction of 4 points in the RASS score was considered to be the MCID within the setting of persistent agitation and delirium. These findings may support future study designs and help with the interpretation of the findings from delirium trials.
